Scan to downloadNxera Pharma Co., Ltd. (4565) Earnings Releases & Disclosures
| Date | Type | Title | Files |
|---|---|---|---|
| 2026-11-04 | — | Nxera Pharma Revises Consolidated Financial Forecast for the Year Ending 31 December 2026 | |
| 2026-11-04 | — | Nxera Pharma Enters into Global License Agreement with AbbVie for NXE0033744, a Novel EP4 Receptor Agonist for Inflammatory Bowel Disease | |
| 2026-10-30 | Earnings Release | Consolidated Financial Results for the Nine Months Ended September 30, 2026 (IFRS) | |
| 2026-10-30 | — | Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter 2026 | |
| 2026-10-28 | — | Nxera Pharma Secures Exclusive Rights to Fabry Disease Phase 3 Oral Therapy Candidate Lucerastat for Japan and Selected Asia Pacific Markets | |
| 2026-10-22 | — | Nxera Pharma Submits Marketing Authorization Application for Vamorolone in South Korea for the Treatment of Duchenne Muscular Dystrophy | |
| 2026-10-20 | — | Introduction of the Executive Officer Performance Stock Option Plan and Issuance of Stock Acquisition Rights Under the Plan | |
| 2026-10-14 | — | Nxera Pharma Enters into Exclusive License, Supply and Commercialization Agreement with Synmosa for QUVIVIQ Across Eight Asia-Pacific Markets | |
| 2026-09-03 | — | Nxera Pharma to Receive $8.6 Million Milestone Payment from Centessa Pharmaceuticals Following Late-stage Development Progress | |
| 2026-08-26 | — | Nxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer's Cognition | |
| 2026-08-07 | Earnings Release | Consolidated Financial Results for the Six Months Ended June 30, 2026 (IFRS) | |
| 2026-08-07 | — | Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter 2026 |
TDnet keeps only 31 days; this site accumulates daily and cannot backfill earlier disclosures.